Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Till Capital Ltd
TIL | US
8.44
USD0.09
1.02%
TIL | US
Loading StockChartView...
About Till Capital Ltd
Sector
Industrials
Industry
Farm & Heavy Construction Machinery
Earnings date
30/06/2024
As of date
14/04/2026
Close
8.44
Open
8.43
High
8.50
Low
8.26
Instil Bio Inc. a clinical-stage biopharmaceutical company develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306 a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha a tumor-associated antigen that is expressed on various solid tumors including ovarian cancer uterine cancer NSCLC and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas Texas.
View LessTIL | US
Risk
46.5
Sharpe
-0.37
Luna's Score
42/100
Recommendation
Sell
Luna says (TIL | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
45.3%1 month
46.5%3 months
46.9%6 months
91.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.32
Debt to equity
0.44
Debt to assets
0.29
Ent. to EBITDA
0.62
Ent. to rev.
43.21K
PEG
-
Other Fundamentals
EBITDA
-66.02M
MarketCap
54.89M
MarketCap(USD)
54.89M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-48.65
Short ratio
0.31
Short perc.
5.07
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.99
Range1M
1.32
Range3M
3.02
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.59
Price X volume
134.67K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.62 | 1.86 | Cheaper |
| Ent. to Revenue | 43,213.90 | 8,644.57 | Expensive |
| PE Ratio | - | - | - |
| Price to Book | 1.32 | 0.80 | Expensive |
| Dividend Yield | - | 1.73 | - |
| Std. Deviation (3M) | 46.94 | 66.59 | Lower Risk |
| Debt to Equity | 0.44 | 0.68 | Cheaper |
| Debt to Assets | 0.29 | 0.33 | Par |
| Market Cap | 54.89M | 162.93M | Emerging |
